GlassScriptPhysician profile
Donna Luke
NPI 1760062038
$11,764.53
in general payments reported to CMS, 2019-2025
51 companies · $3,434 in 2025
The $3,434 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $755 · 2022: $2,084 · 2023: $2,306 · 2024: $3,186 · 2025: $3,434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,925.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,608.96 | 2021-2025 | |
| Acadia Pharmaceuticals INC | $1,038.40 | 2022-2024 | Nuplazid |
| Mdd US Operations, LLC | $1,036.14 | 2022-2025 | Apokyn, Apokyn, Gocovri |
| Ucb, INC. | $716.56 | 2021-2025 | Briviact, Nayzilam, Rystiggo |
| Eisai INC. | $649.48 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $513.80 | 2021-2025 | Austedo Xr, Austedo Xr |
| Pfizer INC. | $488.74 | 2021-2025 | |
| Genzyme Corporation | $483.29 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $472.37 | 2021-2025 | Hyqvia |
| Alexion Pharmaceuticals, INC. | $411.63 | 2023-2025 | Ultomiris |
| Neurocrine Biosciences, INC. | $379.91 | 2022-2025 | Ingrezza, Ongentys |
| Lilly USA, LLC | $375.00 | 2022-2025 | Kisunla, Amyvid, Emgality |
| Otsuka America Pharmaceutical, INC. | $336.93 | 2023-2025 | Rexulti, Nuedexta |
| Alnylam Pharmaceuticals INC. | $297.12 | 2022-2024 | Amvuttra, Onpattro |
| Merz Pharmaceuticals, LLC | $268.74 | 2024-2025 | Inbrija, Xeomin |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Luke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.